We conducted a pilot intervention study using febuxostat against NAFLD in patients with hyperuricemia to determine whether febuxostat reduces serum levels of ALT and AST, two markers of liver injury. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.